Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer
Conditions
Interventions
Docetaxel
Docetaxel and GM-CSF
Locations
4
United States
University of California, San Francisco
San Francisco, California, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Oregon Health and Science University Cancer Institute
Portland, Oregon, United States
University of Washington
Seattle, Washington, United States
Start Date
April 1, 2007
Primary Completion Date
March 1, 2014
Completion Date
May 1, 2014
Last Updated
November 20, 2019
NCT07177937
NCT06926283
NCT06844383
NCT06594926
NCT06487507
NCT05919264
Lead Sponsor
University of California, San Francisco
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions